Evotec - Research never stops
  • Loading...

Archive



Sep 05, 2011

Ad hoc: Evotec and Roche agree to develop compound that could slow the progression of Alzheimer’s disease

Evotec AG and Roche AG today announced that they have entered into an agreement for the development and commercialisation of Evotec’s MAO-B inhibitor...

- read more
Jun 01, 2011

Ad hoc:Evotec acquires compound management business from Galapagos

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Compa...

- read more
May 18, 2011

Ad hoc: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated

Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101.  

- read more
Feb 09, 2011

Ad hoc:Evotec acquires Kinaxo, expanding its drug discovery platform with cutting-edge technologies

 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discov...

- read more